ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2310

Prospective Evaluation of Pulmonary Involvement in Patients with Primary Sjögren’s Disease, Using Pulmonary Function Tests and High Resolution Computed Tomography, Reveals High Prevalence of Subclinical Interstitial Lung Disease, Along with Small Airways Disease

Panagiotis Panagopoulos1, Loukas chatzis2, Eirini Chatzinikita3, Katerina Malagari4, Theodoros Vassilakopoulos3, Athanasios Tzioufas5 and Andreas Goules6, 1Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 2Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, 3Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 42nd Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 5LAIKO HOSPITAL, Athens, Greece, 6GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece

Meeting: ACR Convergence 2024

Keywords: interstitial lung disease, pulmonary, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Sjögren's Syndrome – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) and small airways disease (SAD) are frequent pulmonary manifestations of primary Sjögren’s disease (SjD). The relation between these two entities and their real prevalence in SjD patients with subjective complaints of respiratory disease are still elusive. Our purpose was to describe the clinical, functional and imaging findings of pulmonary disease in SjD and investigate the association with serologic features and the salivary gland biopsy focus score.

Methods: Consecutive SjD patients with respiratory symptoms and/or asymptomatic patients with abnormal pulmonary function tests, followed up in the Department of Pathophysiology (member of the European Reference Network, ERN), were recruited prospectively, from October 2022 to March 2024. Abnormal PFTs were defined as FVC< 80% and/or FEF25-75< 60% and/or DLCO< 70%. A hundred and one patients with primary SjD comprised the study group. All patients: i) underwent pulmonary and small airways function assessment with spirometry, measurement of DLCO, single breath nitrogen washout, impulse oscillometry, ii) high resolution computed tomography (HRCT) of the lungs evaluated blindly by a specialized radiologist for the presence of ILD and SAD according to international consensus criteria1, and iii) replied to specific questionnaires for dyspnea and cough.

Results: The mean±SD age of the 101 (96% females) patients at SjD onset was 50.7±13.1 years and the median disease duration from SjD onset until current evaluation was 10 years (range: 0-38). Eighty five patients were symptomatic. Thirty two (31.7%) patients had findings of ILD on HRCT. No statistical differences were identified between SjD patients with and without ILD in terms of sex, age at SjD, disease duration, treatment modalities and smoking history (Table 1). SjD-ILD patients presented more frequently with dyspnea and cough assessed by the respiratory questionnaires [FACIT-D (median: 38.6 vs. 32.8, p=0.010), SGRQ (median: 19.6 vs. 6.1, p=0.019), CAT (median: 3 vs. 1, p=0.006)] compared to non ILD-SjD patients. They also had worse small airways function indices [lower FEF25-75 (median: 62.5% vs. 86%, p=0.015), higher R5-R20 (median: 0.100 vs. 0.064 kPa/L/s, p=0.030) and more frequently abnormal phase III slope >120% (48% vs. 23%, p=0.031)] as well as SAD findings on HRCT than non-ILD controls (25% vs. 9%, p=0.027). SjD-ILD patients had more frequently elevated CRP at the time of evaluation (28% vs. 7%, p=0.017), higher disease activity (ESSDAI 4 vs. 2, p=0.003), lymphoma history (33% vs. 10%, p=0.005) and a tendency to develop more frequently anti-Ro52 (80% vs. 61%, p=0.071). Interestingly, at SjD diagnosis SjD-ILD patients had higher focus score on salivary gland biopsy (3.56 vs. 1.50, p=0.002) and lower unstimulated salivary flow (0.60 vs. 1.85 ml/15min, p=0.012).

Conclusion: Interstitial lung disease and small airways disease occur frequently among SjD patients. Interstitial lung disease is associated with worse SAD leading to respiratory symptoms and functional lung impairment, as well as higher focus score at SjD diagnosis and higher disease activity.

References
1. Hansell et al. Radiology (2008) 246:697–722.

Supporting image 1

Table 1. Comparison of respiratory features between SjD patients with and without ILD.


Disclosures: P. Panagopoulos: Pfizer, 2; L. chatzis: Pfizer, 2; E. Chatzinikita: None; K. Malagari: None; T. Vassilakopoulos: None; A. Tzioufas: Pfizer, 2; A. Goules: AbbVie/Abbott, 6, Amgen, 1, Pfizer, 2.

To cite this abstract in AMA style:

Panagopoulos P, chatzis L, Chatzinikita E, Malagari K, Vassilakopoulos T, Tzioufas A, Goules A. Prospective Evaluation of Pulmonary Involvement in Patients with Primary Sjögren’s Disease, Using Pulmonary Function Tests and High Resolution Computed Tomography, Reveals High Prevalence of Subclinical Interstitial Lung Disease, Along with Small Airways Disease [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/prospective-evaluation-of-pulmonary-involvement-in-patients-with-primary-sjgrens-disease-using-pulmonary-function-tests-and-high-resolution-computed-tomography-reveals-high-prevalence/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prospective-evaluation-of-pulmonary-involvement-in-patients-with-primary-sjgrens-disease-using-pulmonary-function-tests-and-high-resolution-computed-tomography-reveals-high-prevalence/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology